Bizarre Patents
Apparatus for Simulating a High Five
A self-righting hand-arm configuration which is adapted to pivot when struck by a user, thereby simulating a "high five."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110306753 | Method for Increasing Protein Expression in Cells The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermo... | 12/15/2011 |
| 20110189128 | RECOMBINANT SUPER-COMPOUND INTERFERON This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers... | 08/04/2011 |
| 20110177029 | O-LINKED GLYCOSYLATION USING N-ACETYLGLUCOSAMINYL TRANSFERASES The present invention provides covalent conjugates between a polypeptide and a modifying group, such as a water-soluble polymer (e.g., PEG). The amino acid sequence of the polypeptide includes one or more O-linked glycosylation sequence, each being a substrate for a GIc... | 07/21/2011 |
| 20110171173 | IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly ho... | 07/14/2011 |
| 20110059045 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT The invention relates to therapeutic compositions for the treatment of cancer and, more specifically, compositions containing an agonist ligand for receptor 4-1BB and a type-1 interferon, the simultaneous or sequential delivery of which results in a synergic antitumour ... | 03/10/2011 |
| 20110038834 | NOVEL AVIAN CYTOKINES AND GENETIC SEQUENCES ENCODING SAME The present invention relates generally to novel recombinant polypeptides having avian cytokine properties and to genetic sequences encoding same. More particularly, the present invention is directed to recombinant avian Type III interferon polypeptides, and genetic seq... | 02/17/2011 |
| 20110008283 | INTERFERON FUSION PROTEINS The disclosure relates to interferon fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.... | 01/13/2011 |
| 20100303759 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human inte... | 12/02/2010 |
| 20100273215 | Secretion Yield of a Protein of Interest by in vivo Proteolytic Processing of a Multimeric Precursor The invention relates to a nucleic acid molecule encoding a multimeric precursor which after transcription is specifically cleaved in vivo to form multiple copies of a protein of interest. The invention further relates to a cell comprising this nucleic acid molecule and... | 10/28/2010 |
| 20100266536 | NEW TYPE OF CONSENSUS INTERFERON AND PREPARATION METHOD THEREOF The invention relates to variants of consensus interferon protein with improved properties, such as improved anti-viral activity, and use thereof. The variants are also easier to renature after denaturant treatment. The invention also relates to the preparation method o... | 10/21/2010 |
| 20100260704 | HUMAN INTERFERON-GAMMA (INFGAMMA) VARIANTS The present invention relates to human interferon gamma variants with improved thermostability, to a nucleic acid encoding said variants, to a pharmaceutical composition containing them, and to their use for the treatment of a viral infection and of cancer.... | 10/14/2010 |
| 20100221222 | INTERFERONS, USES AND COMPOSITIONS RELATED THERETO The present disclosure provides isolated Interferonα nucleic acids and polypeptides. The disclosure also provides antibodies which specifically recognize the subject Interferonα polypeptides, expression vectors containing the subject nucleic acids, and host cells expr... | 09/02/2010 |
| 20100189682 | Biologically active proteins having increased In Vivo and/or In Vitro stability The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these enti... | 07/29/2010 |
| 20100129904 | RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human inte... | 05/27/2010 |
| 20100083403 | PRODUCTION OF PEPTIDES AND PROTEINS BY ACCUMULATION IN PLANT ENDOPLASMIC RETICULUM-DERIVED PROTEIN BODIES A nucleic acid molecule is disclosed as containing a first nucleic acid sequence comprising a nucleotide sequence that encodes γ-zein protein, or a fragment thereof capable of directing and retaining a protein towards the endoplasmic reticulum (ER) of a plant cell; a s... | 04/01/2010 |
| 20100081789 | Novel Vectors for Production of Interferon Novel compositions for the production of interferons such as interferon-α 2a, interferon-α 2b, or interferon-β 1a (IFN-α 2a, IFN-α 2b, or IFN-β 1a) are provided. The compositions comprise components of vectors, such as a vector backbone, a promoter, and a gene of ... | 04/01/2010 |
| 20100074866 | INTERFERON ALPHA MUTANT AND ITS POLYETHYLENE GLYCOL DERIVATIVE IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is ... | 03/25/2010 |
| 20100061961 | RECOMBINANT SUPER-COMPOUND INTERFERON This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and, therefore, is useful in preventing and treating viral diseases and... | 03/11/2010 |
| 20100003721 | HUMAN INTERFERON-BETA MUTEIN The present invention relates to a human interferon-beta mutein. In particular, the present invention relates to the human interferon-beta mutein having one or two additional sugar chains compared to natural human interferon-beta.... | 01/07/2010 |
| 20090311216 | RECOMBINANT INTERFERON-BETA WITH ENHANCED BIOLOGICAL ACTIVITY Human interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native human interferon-β, is recombinantly replaced with an aspartate residue exhibit a biological activity of human interferon-β (e.g. IFN-β 1b) at an increased ... | 12/17/2009 |
| 20090269306 | N-TERMINAL MODIFIED INTERFERON-ALPHA A method of reducing formation of non-natural disulfide bonds in a mature IFN-α by adding one or more amino acid residues to its N-terminus cystein. Also disclosed herein is the IFN-α thus modified.... | 10/29/2009 |
| 20090208454 | MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES Modified interferon beta polypeptides and uses thereof are provided.... | 08/20/2009 |
| 20090175819 | MOLECULE AND CHIMERIC MOLECULES THEREOF The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule that comprises a dimeric 4-helix bundle, such as IFN-a2B, IFN-b1, IFN-g, IL-10 or i... | 07/09/2009 |
| 20090131318 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytoki... | 05/21/2009 |
| 20090123974 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytoki... | 05/14/2009 |
| 20090092581 | Interferons of rhesus and cynomolgus origin and uses thereof Disclosed are interferons of Rhesus and Cynomolgus origin and methods of production and use thereof.... | 04/09/2009 |
| 20090087411 | Long-acting interferons and derivatives thereof and methods thereof A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of usi... | 04/02/2009 |
| 20090053147 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytoki... | 02/26/2009 |
| 20090030183 | Interferon Beta-Like Molecules The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one i... | 01/29/2009 |
| 20090025106 | C-TERMINALLY TRUNCATED INTERFERON The invention described herein provides a C-terminally truncated interferon having enhanced biological activity and the polynucleotides encoding such interferon. Also provided are methods for producing and using such truncated interferon.... | 01/22/2009 |
| 20090022761 | Enhancement of Immune Response to Vaccine by Interferon Alpha Exogenous cDNA capable of expressing interferon″ activity, exogenous interferon″ protein, inducers of endogenous interferon″ protein activity, inducers of endogenous interferon $ protein activity, inducers of endogenous interferon′ activity, or inducers of other... | 01/22/2009 |
| 20090004156 | POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha17 GENE The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNα-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNα-17 protein comprising at least one mutation caused by at least one SNP of th... | 01/01/2009 |
| 20080305080 | RECOMBINANT SUPER-COMPOUND INTERFERON This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers... | 12/11/2008 |
| 20080279823 | Recombinant Interferon 2alpha (Infalpha2) Mutants The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof that have improved specific agonist or antagonist activity as compared to wild-type IFNα2. The present invention further provides pharmaceutical compositions ... | 11/13/2008 |
| 20080226597 | EVOLVED INTERFERON-ALPHA POLYPEPTIDES The present invention provides evolved interferon-alpha polypeptides, and conjugates thereof, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressi... | 09/18/2008 |
| 20080219952 | Process For the Preparation of Glycosylated Interferon Beta The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.... | 09/11/2008 |
| 20080176323 | Polynucleotides encoding E38N interferon gamma polypeptides A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one intro... | 07/24/2008 |
| 20080171363 | INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptid... | 07/17/2008 |
| 20080166319 | RECOMBINANT INTERFERON ALPHA2 (IFNALPHA2) MUTANTS AND METHODS OF USE THEREOF The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, ... | 07/10/2008 |
| 20080160030 | Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does no... | 07/03/2008 |
